The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth ...

Receptor-interacting protein kinase 1 (RIPK1) helps promote the survival of cancer cells, and degrading it can sensitize ...

Biopharma financing activity from January through November reveals an environment that has cycled through dramatic peaks and ...

Crescent Biopharma Inc. has announced a new partnership with Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. and reported ...

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic ...

Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to ...

The overexpression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is tied to poor prognosis in several cancer ...

After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge ...

The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome ...

Shandong Luye Pharmaceutical Co. Ltd. has identified salts of CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Avencell Therapeutics Inc. has received clinical trial clearances from the FDA and EMA to conduct a phase I/II trial (Quadvance) of AVC-203 for the treatment of relapsed or refractory B-cell ...

Neurimmune AG has expanded its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, Astrazeneca Rare Disease by entering into an exclusive global collaboration and license ...